QNRX Valuation
Quoin Pharmaceuticals Ltd
$
7.180
- Overview
- Forecast
- Valuation
- Earnings
QNRX Relative Valuation
QNRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, QNRX is overvalued; if below, it's undervalued.
Historical Valuation
Quoin Pharmaceuticals Ltd (QNRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.12. The fair price of Quoin Pharmaceuticals Ltd (QNRX) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：7.18
Fair
-0.28
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Quoin Pharmaceuticals Ltd. (QNRX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.06
EV/EBIT
Quoin Pharmaceuticals Ltd. (QNRX) has a current EV/EBIT of 0.06. The 5-year average EV/EBIT is -0.08. The thresholds are as follows: Strongly Undervalued below -2.65, Undervalued between -2.65 and -1.37, Fairly Valued between 1.20 and -1.37, Overvalued between 1.20 and 2.49, and Strongly Overvalued above 2.49. The current Forward EV/EBIT of 0.06 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Quoin Pharmaceuticals Ltd. (QNRX) has a current PS of 0.00. The 5-year average PS is 0.19. The thresholds are as follows: Strongly Undervalued below -1.27, Undervalued between -1.27 and -0.54, Fairly Valued between 0.92 and -0.54, Overvalued between 0.92 and 1.65, and Strongly Overvalued above 1.65. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Quoin Pharmaceuticals Ltd. (QNRX) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.49. The thresholds are as follows: Strongly Undervalued below -2.51, Undervalued between -2.51 and -1.50, Fairly Valued between 0.53 and -1.50, Overvalued between 0.53 and 1.54, and Strongly Overvalued above 1.54. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Quoin Pharmaceuticals Ltd. (QNRX) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.00. The thresholds are as follows: Strongly Undervalued below -11.38, Undervalued between -11.38 and -5.69, Fairly Valued between 5.69 and -5.69, Overvalued between 5.69 and 11.38, and Strongly Overvalued above 11.38. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Quoin Pharmaceuticals Ltd (QNRX) has a current Price-to-Book (P/B) ratio of 1.62. Compared to its 3-year average P/B ratio of 0.51 , the current P/B ratio is approximately 219.41% higher. Relative to its 5-year average P/B ratio of 0.96, the current P/B ratio is about 69.12% higher. Quoin Pharmaceuticals Ltd (QNRX) has a Forward Free Cash Flow (FCF) yield of approximately -258.16%. Compared to its 3-year average FCF yield of -191.13%, the current FCF yield is approximately 35.07% lower. Relative to its 5-year average FCF yield of -169.22% , the current FCF yield is about 52.56% lower.
1.62
P/B
Median3y
0.51
Median5y
0.96
-258.16
FCF Yield
Median3y
-191.13
Median5y
-169.22
Competitors Valuation Multiple
The average P/S ratio for QNRX's competitors is 0.30, providing a benchmark for relative valuation. Quoin Pharmaceuticals Ltd Corp (QNRX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of QNRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of QNRX in the past 1 year is driven by Unknown.
People Also Watch
SONN
Sonnet Biotherapeutics Holdings Inc
3.950
USD
+32.11%
ALLR
Allarity Therapeutics Inc
1.000
USD
+4.17%
STKH
Steakholder Foods Ltd
0.899
USD
+2.39%
NCNA
NuCana PLC
4.550
USD
-3.40%
XPON
Expion360 Inc
1.310
USD
+11.02%
IMTE
Integrated Media Technology Ltd
0.960
USD
-1.23%
ONCO
Onconetix Inc
3.100
USD
+4.73%
GLMD
Galmed Pharmaceuticals Ltd
1.460
USD
+2.82%
FAQ
Is Quoin Pharmaceuticals Ltd (QNRX) currently overvalued or undervalued?
Quoin Pharmaceuticals Ltd (QNRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.12. The fair price of Quoin Pharmaceuticals Ltd (QNRX) is between to according to relative valuation methord.
What is Quoin Pharmaceuticals Ltd (QNRX) fair value?
How does QNRX's valuation metrics compare to the industry average?
What is the current P/B ratio for Quoin Pharmaceuticals Ltd (QNRX) as of Aug 13 2025?
What is the current FCF Yield for Quoin Pharmaceuticals Ltd (QNRX) as of Aug 13 2025?
What is the current Forward P/E ratio for Quoin Pharmaceuticals Ltd (QNRX) as of Aug 13 2025?